Carregant...
Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
The introduction of immunotherapy to treat recurrent/metastatic head and neck squamous cell carcinoma in 2016 has provided new valuable treatment options to many cancer patients. Pembrolizumab and nivolumab, which are classified as immune checkpoint inhibitors of programmed cell death protein 1, hav...
Guardat en:
| Publicat a: | J Adv Pract Oncol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Harborside Press LLC
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7522658/ https://ncbi.nlm.nih.gov/pubmed/33014516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.2.12 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|